Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders
MucopolysaccharidosisHurler Syndrome11 moreRationale: Chemotherapy administration before a donor stem cell transplant is necessary to stop the patient's immune system from rejecting the donor's stem cells. When healthy stem cells from a donor are infused into the patient, the donor white blood cells can provide the missing enzyme that causes the metabolic disease. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving a monoclonal antibody, alemtuzumab, before transplant and cyclosporine and mycophenolate mofetil before and after transplant may stop this from happening. This may be an effective treatment for inherited metabolic disorders. Purpose: The design of this study is to achieve donor cell engraftment in patients with standard-risk inherited metabolic diseases with limited peri-transplant morbidity and mortality. This will be achieved through the administration of the chemotherapy regimen described. The intention is to follow transplanted patient for years after transplant monitoring them for complications of their disease and assisting families with a multifaceted interdisciplinary approach.
Longitudinal Studies of Brain Structure and Function in MPS Disorders
Mucopolysaccharidosis Type IMucopolysaccharidosis Type II3 moreNeurobehavioral function and quality of life are compromised in many patients with mucopolysaccharidosis (MPS) disorders. The long-term goals of this research are to: 1) more accurately inform patients/parents regarding potential neurobehavioral outcomes; 2) develop sensitive measures of disease progression and central nervous system (CNS) treatment outcome; and 3) help clinical researchers develop direct treatments for specific brain structures/functions. The investigators hypothesize that specific and localized neuroimaging and neuropsychological findings and their relationship will be distinct for each MPS disorder. It is further hypothesized that without treatment, functions will decline and structure will change over time in a predictable fashion, and will be related to locus of abnormality and stage of disease.
Biomarker for Sly Disease (MPS VII) (BioSly)
Developmental DelaySkeletal Abnormalities2 moreDevelopment of a new MS-based biomarker for the early and sensitive diagnosis of Sly disease from blood (plasma)
Expanded Access to Mepsevii
MPS VIIMucopolysaccharidosis VII1 moreIndividual patient expanded access requests may be considered for patients who have no other treatment options